335 results on '"Curigliano, A."'
Search Results
2. Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers
3. Unfavorable carcinoma of unknown primary with a gastrointestinal profile: a retrospective study
4. Interstitial lung disease in patients enrolled in early-phase clinical trials: the ILDE study
5. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer
6. A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies
7. “Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper”
8. Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials
9. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)
10. Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer
11. The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer
12. Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review
13. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
14. ESMO expert consensus statements on the screening and management of financial toxicity in patients with cancer
15. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer
16. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial
17. Comparison of long-term outcome between clinically high risk lobular versus ductal breast cancer: a propensity score matched study
18. Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer
19. Policy strategies for capacity building and scale up of the workforce for comprehensive cancer care: a systematic review
20. Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer
21. Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)
22. Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00
23. Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)
24. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer
25. International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations
26. EUSOMA quality indicators for non-metastatic breast cancer: An update
27. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
28. Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
29. Advancing equitable and personalized cancer care: Novel applications and priorities of artificial intelligence for fairness and inclusivity in the patient care workflow
30. Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)
31. A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases
32. The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development
33. ESMO Recommendations on clinical reporting of genomic test results for solid cancers
34. Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD)
35. Treatment and outcomes in breast cancer patients: A cross section study from the EUSOMA breast centre network
36. Primary malignant phyllodes tumors of the breast: A retrospective analysis from a referral center
37. Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response
38. ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing
39. Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study
40. Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread
41. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023
42. ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)
43. Leptomeningeal metastasis from solid tumours: EANO–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
44. Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain
45. Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials
46. The immunogram of inflammatory breast cancer
47. Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis
48. Faecal microbiota composition is related to response to CDK4/6-inhibitors in metastatic breast cancer: A prospective cross-sectional exploratory study
49. A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data
50. Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.